Pandomics

How it works

Get the complete report on the data relevant for your project and filter it with multiple tags such as data source, data type, cell line, donor age, disease, etc.

Select data from our exhaustive database or upload your own data

Use state-of-art tools to analyse data

Visualise and explore results

Use state-of-the-art methods of omics data analysis and get results on gene, protein and signaling pathway levels. Compare the results for various data sets.

Get the statistics for upregulated and downregulated features

Explore the power of data visualization with Pandomics. Draw, customize and save charts, tables and integrated reports for your project.

Visualize the signal transduction through the signaling axes, identify hubs and perturbed subnetworks. Use pathway perturbation signatures to find disease targets and molecular candidates.

Project your data into one or more signaling pathway ontologies

Get the comprehensive disease profile and use it for AI-powered drug discovery and biomarker development. Collect the data on the highest scored molecules and targets.

Pipeline

A huge part of Insilico Medicine drug discovery pipeline is now available with Pandomics
More than
2 000 000
samples
More than 2 000
Experimental
platforms
Including transcripomics, proteomics and other data types.

Pandomics Publications

16 November, 2016

In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development


22 May, 2017

In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia


21 February, 2018

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

28 June, 2018

Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1


8 June, 2017

An analysis of gene expression data involving examination of signaling pathways activation reveals new insights...


23 February, 2018

Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation...